VANCOUVER, BRITISH COLUMBIA--(Marketwire - November 21, 2007) - Tekmira Pharmaceuticals Corporation (“Tekmira”) (TSX: TKM) reported today that two of its partners, Aradigm Corporation (“Aradigm”) (OTCBB: ARDM) and Hana Biosciences, Inc. (“Hana”) (NASDAQ: HNAB) have initiated two separate Phase 2 clinical trials using technology licensed from Tekmira.
